Phaseline

Companies › Aadi Bioscience

Aadi Bioscience: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 2Tumor; Endometrial Cancer; Tumor, SolidDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05103358SirolimusPhase 2TumorOncologyDec 2024
NCT05661461SirolimusPhase 1Tumor, SolidOncologyAug 2025
NCT05997017SirolimusPhase 2Endometrial CancerOncologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

FKBP1A (1)

Companies with the same targets

Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis Rapamycin Holdings AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Eyestem Research

Companies built like this

Rapamycin Holdings Mercator MedSystems Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.